It was first approved by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of HER2-positive breast cancer, with subsequent approval by the European Medicines Agency (EMA) for the same indication in January 2021 [12,13]. This evidence concerns the gene ERBB2 and breast carcinoma.